Cantor Fitzgerald analyst Craig Bijou believes shares of Globus Medical (GMED) are attractive at current levels. He reiterates an Overweight rating on the name with a $55 price target. The analyst expects Globus to "bounce back" in Q2. Further, there are multiple Excelsius enhancements expected in the second half of 2019 that should give the company a competitive advantage, Bijou tells investors in research note. He also believes the momentum of the company's underlying core spine business should continue in the second half of the year. The analyst sees limited downside risk in the shares as he believes the worst case Medtronic (MDT) competitive fears are likely reflected in Globus Medical's current price.